Clinical Research Directory
Browse clinical research sites, groups, and studies.
An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression
Sponsor: Beckley Psytech Limited
Summary
An open-label, multi-centre, Phase 2a study to evaluate the safety, tolerability, and pharmacodynamics of one and two doses of intranasal BPL-003 combined with psychological support, in patients with treatment resistant depression when administered as monotherapy or as adjunctive therapy with defined SSRIs (citalopram, escitalopram, sertraline or fluoxetine).
Official title: An Open-Label, Phase 2a Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
64
Start Date
2023-02-10
Completion Date
2026-11
Last Updated
2025-11-28
Healthy Volunteers
No
Conditions
Interventions
BPL-003
Experimental BPL-003 arms: will investigate one of two doses of BPL-003 (Part 1) and two doses of BPL-003 (Part 2)
Locations (3)
MAC Clinical Research
Liverpool, United Kingdom
Hammersmith Medicines Research
London, United Kingdom
King's College London, Clinical Trials Facility
London, United Kingdom